{"disease":{"id":"idiopathic-short-stature","name":"idiopathic short stature"},"drugs":{"marketed":[{"drug_id":"somapacitan-beco","indication_name":"Idiopathic Short Stature","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SOGROYA","generic_name":"SOMAPACITAN-BECO","company_name":"NOVO NORDISK INC","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"somapacitan","indication_name":"Idiopathic Short Stature","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sogroya","generic_name":"SOMAPACITAN","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Sogroya works by binding to the growth hormone receptor, mimicking the action of growth hormone and stimulating growth and development."},{"drug_id":"ngenla-somatrogon","indication_name":"Idiopathic short stature in pediatric patients 2 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"NGENLA (Somatrogon)","generic_name":"ngenla-somatrogon","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"Recombinant human growth hormone","quality_score":40,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06309979","title":"A Study to Assess Growth in Children With Idiopathic Short Stature","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"BioMarin Pharmaceutical","has_results":false},{"nct_id":"NCT05858606","title":"Multidisciplinary Evaluation and a Genome-wide Analysis in a Cohort of Idiopathic Short Stature Patients","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT07450053","title":"A Study (Phase 1b/2) of GenSci134 in Children With Idiopathic Short Stature (ISS)","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":128,"lead_sponsor_name":"Changchun GeneScience Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05838885","title":"A Trial of YPEG-rhGH in Children With Short Stature","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"Xiamen Amoytop Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT01778023","title":"Efficacy and Safety of Recombinant Human Growth Hormone on Height Velocity in Subjects With Idiopathic Short Stature","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT04020913","title":"Skeletal Muscle Effects of GH in Boys","phase":"","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Nemours Children's Clinic","has_results":false},{"nct_id":"NCT05894876","title":"A Study of the Genetic Basis of Response to Growth Hormone Treatment in Children With Idiopathic Short Stature","phase":"","overall_status":"TERMINATED","enrollment_count":43,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT01401244","title":"Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}